History
A list of downloadable documents created during development.
Background information
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Appendix A - decision paper presented to the Institute's Guidance Executive
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: equality impact assessment - guidance development
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: equality impact assessment - guidance development
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: final appraisal determination
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: final appraisal determination document
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: evaluation report
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: pre-meeting briefing
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Evidence Review Group report
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Evidence Review Group report - factual accuracy check
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: erratum to the Evidence Review Group report
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: erratum
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: post-Appraisal Committee meeting erratum
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Bristol-Myers Squibb and Pfizer
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: clarification
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: NICE clarification letter to the manufacturer
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Bristol-Meyers Squibb and Pfizer response to clarification points
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: patient group, professional and NHS organisation submission statements
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: AntiCoagulant Europe
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Arrhythmia Alliance
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Clinical Leader of Thrombosis
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Heart Rhythm UK
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Royal College of Nursing
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Royal College of Physicians and British Society of Haematology
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: expert written personal statements
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Diane Eaton - appendix K patient/carer declaration statement
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Jo Jerrome - appendix K patient/carer declaration statement
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Professor Gregory Lip - appendix D clinical specialist statement
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Dr Francis Murgatroyd - appendix K clinical specialist statement
-
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Dr Watts - appendix K clinical specialist statement
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: response to consultee and commentator comments on the provisional matrix - June 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: response to consultee and commentator comments on the provisional matrix - June 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: response to consultee and commentator comments on the draft remit and draft scope - June 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: response to consultee and commentator comments on the draft remit and draft scope - June 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: final scope - June 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: final scope - June 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: final matrix - June 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: final matrix - June 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: equality impact assessment - scoping - June 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: equality impact assessment - scoping - June 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: appendix B - provisional matrix February 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: appendix B - provisional matrix February 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: appendix A - draft scope for consultation February 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: appendix A - draft scope for consultation February 2012
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: appendix B - draft scope for consultation (pre-referral) July 2011
-
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: appendix B - draft scope for consultation (pre-referral) July 2011
-